Clinical trials: Treatment Related Cancer
Pain, Cancer
A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients
The purpose of the study is to determine the effect of Egalet® Morphine once daily compared to MST Continus twice daily on pain intensity and use of rescue medication for break through pain after 2 weeks of treatment in patients…
- Trial name
- NCT00446069
- Testing
- Morphine Sulphate
- Where
- 8 sites in Lithuania, Poland
- Volunteers
- 36 people
- Sponsor
- Egalet Ltd
Mantle Cell Lymphoma
A Disease Registry of Patients With Mantle Cell Lymphoma
The purpose of this study is to create a patient registry in order to assess treatment patterns, physician reported clinical outcomes and patient-reported health-related quality of life among patients diagnosed with Mantle Cell…
- Trial name
- SUMMIT (NCT03816683)
- Where
- 32 sites in United States
- Volunteers
- 227 people
- Sponsor
- AstraZeneca
Malignant Neoplasm
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.
- Trial name
- NCT07247110
- Testing
- MK-4716, Pembrolizumab, Cetuximab
- Where
- 21 sites in United States, Australia and 5 more
- Volunteers
- 250 people
- Sponsor
- Merck Sharp & Dohme LLC
Hematologic Diseases, Hematologic Malignancies
Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
The purpose of this study is to determine the maximum tolerated dose and evaluate the safety of the administration of donor lymphocytes depleted of alloreactive T-cells following a stem cell transplant from a related…
- Trial name
- NCT00993486
- Testing
- Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- Kiadis Pharma
Cancer-related Fatigue
PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients
The objective of this study is to assess the efficacy of weekly PG2 regimen as a complementary treatment for patients with recurrent unresectable (local or regional) or metastatic breast cancer who experienced moderate to severe…
- Trial name
- NCT05440227
- Testing
- PG2 Lyo. Injection 500mg
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- PhytoHealth Corporation
Cancer
Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells
A retrospective, observational study conducted on cancer patients receiving a drug that blocks certain proteins made by some types of immune system cells
- Trial name
- NCT03644498
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 1,056 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor…
- Trial name
- NCT05882734
- Testing
- M1774, Cemiplimab
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 61 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Bone Cancer, Bone Metastases
Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System
The goal of this prospective, non-randomized, single-arm, phase 2 study is to evaluate the safety and effectiveness of this treatment using this ExAblate conformal system in the treatment of pain resulting from metastatic bone…
- Conditions
- Bone Cancer, Bone Metastases, Pain
- Trial name
- NCT01085565
- Testing
- ExAblate 2100
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- InSightec
Palmar-Plantar Erythrodysesthesia, Breast Cancer
Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome
The purpose of this research study is to see if combining uracil cream (UTC) with capecitabine (Xeloda) can prevent Hand-Foot Syndrome.
- Trial name
- NCT01100463
- Testing
- Cream, 0.1% Uracil Cream
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Nanometics (d.b.a. PHD Biosciences)
Gastrointestinal Neuroendocrine Tumours
Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours
The purpose of this study is to evaluate the utility of the QLQ-GINET21 in making clinical and therapeutic decisions.
- Trial name
- QUALINETS (NCT02853422)
- Where
- 32 sites in Portugal, Spain
- Volunteers
- 199 people
- Sponsor
- Ipsen
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
This is study with SPI-62 to evaluate the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor. Each subject will receive 2mg of SPI-62 daily.
- Conditions
- Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
- Trial name
- ACSPIRE (NCT05436639)
- Testing
- SPI-62 dose
- Where
- 5 sites in United States, Romania and 1 more
- Volunteers
- 30 people
- Sponsor
- Sparrow Pharmaceuticals
Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk
A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies
The study is being conducted to evaluate the preference, and safety of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of chemotherapy-related moderate to severe neutropenia of Patients with nonmyeloid malignancies.
- Trial name
- NCT06254742
- Testing
- HHPG-19K Injection
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Malignant Melanoma
Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
The main purpose of this study was to evaluate the impact on pyrexia-related outcomes of an adapted pyrexia adverse event (AE)-management algorithm, as well as safety, efficacy and health-related outcomes.
- Trial name
- COMBI-APlus (NCT03551626)
- Testing
- Dabrafenib, Trametinib
- Where
- 100 sites in Argentina, Australia and 21 more
- Volunteers
- 552 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Pleural Effusion
A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion
To evaluate the safety and tolerability of single dose of SCB-313 by intrapleural injection.To evaluate the safety and tolerability of repeated dose of SCB-313 by intrapleural injection once a day for 3 days, and to determine the…
- Trial name
- NCT04123886
- Testing
- SCB-313
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
Advanced Solid Tumor, Tumor Associated Lymph Node T Cell
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
A total of 17 to 23 participants are anticipated to be enrolled in the Phase I clinical trial, which is further divided into two distinct parts: one part involves single-agent cell therapy, while the other entails a combination…
- Conditions
- Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy
- Trial name
- TAL-T (NCT06302062)
- Testing
- Tumor Associated Lymph node T cell, cyclophosphamide, IL-2
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
Oropharyngeal Cancer, Human Papilloma Virus
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
This is a multicenter, open-label, Phase I, first-in-human trial to characterize the safety and clinical activity of an antigen-specific CD8+ T-cell product in patients with relapsed or refractory locally advanced or metastatic…
- Conditions
- Oropharyngeal Cancer, Human Papilloma Virus, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05582590
- Testing
- Fludarabine, Cyclophosphamide, NEXI-003 T cells
- Volunteers
- 36 people
- Sponsor
- NexImmune Inc.
Prostate Cancer
Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy
The objective of the study is to compare the evolution over 6 months of Health-Related Quality of Life (HRQOL) among different age groups in subjects with prostate cancer treated with GnRH agonist therapy.
- Trial name
- PRISME (NCT03516110)
- Testing
- Data collection
- Where
- France
- Volunteers
- 831 people
- Sponsor
- Ipsen
Cancer-related Malnutrition
Efficacy Study of Long-term Parenteral Nutrition With SmofKabiven® E in Lung Cancer Patients Under Anticancer Therapy
The purpose of this study is to determine the efficacy of long-term addition of SmofKabiven® E to normal oral nutrition after routine dietary counseling as compared to standard of care nutrition in which oral nutrition is the…
- Trial name
- NCT03355079
- Testing
- SmofKabiven® E
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Fresenius Kabi
Opioid Use Disorder, Moderate
Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy
A Phase 1, Single Dose, Open-label, Safety, Tolerability, and Pharmacokinetic Study of LYN-014 in Individuals with Opioid Use Disorder Who are Stable on Methadone Therapy
- Trial name
- NCT05251376
- Testing
- Levomethadone HCl, Methadone, Morphine Sulfate
- Sponsor
- Lyndra Inc.
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated…
- Conditions
- Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
- Trial name
- NCT04924075
- Testing
- Belzutifan
- Where
- 84 sites in United States, Australia and 20 more
- Volunteers
- 355 people
- Sponsor
- Merck Sharp & Dohme LLC